Teva Pharmaceutical Industries Ltd. $TEVA Position Increased by Russell Investments Group Ltd.

Key Points

• Russell Investments Group Ltd. increased its stake in Teva Pharmaceutical Industries by 30% in Q1 by purchasing an additional 61,330 shares, raising its total holdings to 265,777 shares valued at approximately $4.08 million.
• Several other hedge funds also expanded their investments in Teva, with significant buys reported by Public Sector Pension Investment Board and Todd Asset Management LLC, among others.
• Teva reported an earnings per share (EPS) of $0.66 for the last quarter, surpassing analysts' expectations, and set a FY 2025 EPS guidance between $2.500-$2.600.

Russell Investments Group Ltd. grew its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 30.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 265,777 shares of the company's stock after buying an additional 61,330 shares during the quarter. Russell Investments Group Ltd.'s holdings in Teva Pharmaceutical Industries were worth $4,085,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Ion Asset Management Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company's stock valued at $807,766,000 after acquiring an additional 409,778 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 1.2% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company's stock worth $404,775,000 after purchasing an additional 300,000 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 197,885.2% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after purchasing an additional 22,044,407 shares in the last quarter. Duquesne Family Office LLC lifted its stake in shares of Teva Pharmaceutical Industries by 530.1% during the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after purchasing an additional 7,569,450 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of Teva Pharmaceutical Industries by 40.6% during the fourth quarter. Janus Henderson Group PLC now owns 6,737,625 shares of the company's stock worth $148,497,000 after purchasing an additional 1,945,688 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Up 0.1%

NYSE TEVA traded up $0.03 during trading hours on Wednesday, reaching $18.18. 4,026,754 shares of the company traded hands, compared to its average volume of 12,112,677. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The stock has a market capitalization of $20.85 billion, a PE ratio of -113.47, a PEG ratio of 1.07 and a beta of 0.62. The company has a 50 day moving average of $16.79 and a two-hundred day moving average of $16.29.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same period in the prior year, the firm posted $0.61 EPS. The firm's revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider owned 6,774 shares of the company's stock, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the transaction, the executive vice president owned 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 65,001 shares of company stock valued at $996,958 in the last quarter. Insiders own 0.55% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on TEVA. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $24.71.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.